Exchange: NASDAQ·Updated 05:41 PM EDT

RPID News

News
all
press releases
After Plunging 33.7% in 4 Weeks, Here's Why the Trend Might Reverse for Rapid Micro Biosystems (RPID)
Rapid Micro Biosystems (RPID) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
More News
Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID)
The heavy selling pressure might have exhausted for Rapid Micro Biosystems (RPID) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?
Rapid Micro Biosystems (RPID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -3.85% and +3.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates
Hyperfine (HYPR) delivered earnings and revenue surprises of 0.00% and -7.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of +46.67% and +7.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -24.00% and +6.69%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Lags Revenue Estimates
ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -16.36% and -1.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Rapid Micro Biosystems Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga
Electromed, Inc. (ELMD) Q3 Earnings and Revenues Top Estimates
Electromed (ELMD) delivered earnings and revenue surprises of +34.62% and +4.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.